Latest News and Press Releases

50% of patients in the Phase 2b CONTROL study have now been randomized despite COVID-19 disruptions in the trial marketplace Cash Position of $10.4 Million at December 31, 2020  BASKING RIDGE, NJ,...

- Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe - Basking Ridge, N.J., March 17, 2021 (GLOBE...

- Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder  - Company Awarded Final Tranche of $1.5 Million FDA Orphan Products Clinical Trials...

WOODCLIFF LAKE, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on...

Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire -- Timber Pharmaceuticals, Inc....

Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022 WOODCLIFF LAKE, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc....

- Formal notice confirms intent to grant patent for pharmaceutical isotretinoin composition - WOODCLIFF LAKE, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals,...

Call to be held on Thursday, December 17th at 11:00am EST WOODCLIFF LAKE, N.J., Dec. 10, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE...

Presentation on Tuesday December 15th  at 10:40am EST LOS ANGELES, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American:...

WOODCLIFF LAKE, NJ, Nov. 20, 2020 (GLOBE NEWSWIRE) -- NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...